stockrowDaxor Corporation
DXR Healthcare Medical Instruments & Supplies
Daxor Corporation’s revenue for fiscal 2022 (year ended December 2022) was −$353,400.00.
Follow DXR
Alert me
Daxor Corporation (DXR) Piotroski F-score
Daxor Corporation's Piotroski F-score for fiscal 2022 cannot be worked out: current assets, current liabilities, and gross profit not reported.
Piotroski F-score, annual
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|
How fiscal 2022’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 18.75% | 22.86% | Pass | 1 |
| Positive operating cash flow | (3.46m) | (2.83m) | Fail | 0 |
| Rising return on assets | 18.75% | 22.86% | Fail | 0 |
| Cash flow above net income | (8.64m) | (7.58m) | Fail | 0 |
| Falling long-term leverage | 0.04 | 0.15 | Pass | 1 |
| Rising current ratio | — | — | n/a | — |
| No new shares issued | 4,083,800 | 4,036,700 | Fail | 0 |
| Rising gross margin | — | — | n/a | — |
| Rising asset turnover | (0.01) | (0.13) | Pass | 1 |
| Piotroski F-score | n/a — current assets, current liabilities, and gross profit not reported | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| NEPH Nephros Inc. compare | 7 |
| POCI Precision Optics Corp. compare | 5 |
| KRMD KORU Medical Systems, Inc. compare | 5 |
| STXS Stereotaxis Inc. compare | 5 |
| HBIO Harvard Bioscience, Inc. compare | 4 |
| MLSS Milestone Scientific, Inc. compare | 2 |
| ZTEKF Zentek Ltd. compare | 1 |
| DXR Daxor Corporation | — |
| DAVI Davion Healthcare PLC compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover